From Zacks Investment Research: 2025-05-28 12:36:00

Eli Lilly (LLY) has agreed to acquire SiteOne Therapeutics for $1 billion, enhancing its neuroscience pipeline with non-opioid pain treatments. SiteOne’s lead asset, STC-004, aims to block pain signals without opioids, showing positive early results. The deal also adds other drugs targeting pain and hyperexcitability. Eli Lilly’s stock performance aligns with the industry. The acquisition diversifies its pain pipeline, aligning with FDA-approved non-opioid pain drugs. SiteOne benefits from Eli Lilly’s commercial expertise. Eli Lilly currently holds a Zacks Rank #3.



Read more at Zacks Investment Research: Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer – May 28, 2025